Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT05144217
Other study ID # TMP-2501-2019-2
Secondary ID
Status Active, not recruiting
Phase Phase 2/Phase 3
First received
Last updated
Start date June 23, 2021
Est. completion date December 31, 2022

Study information

Verified date November 2021
Source Fraunhofer Institute for Molecular Biology and Applied Ecology
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

In this clinical study silymarin will be administered in different dosages and compared to placebo in order to address if the liver protecting features of silymarin, measured by changes of liver enzyme concentration, can be improved in patients with drug-induced elevated liver enzymes or drug-induced hepatocellular liver injury with higher systemic bioavailabilities due to administration of higher oral dosages or administration of higher administration frequency over a 35-day treatment period.


Description:

In clinical routine care, drug-induced elevation of liver enzymes occurs often in parallel to new treatment initiation, possibly leading to interruption of treatment strategies if liver enzyme elevation does not normalize within 2 to 4 weeks. Liver injury from medications usually occurs within 6 months of drug initiation and typically within the first 1-4 weeks1. In general, drug-induced liver injury (DILI) is related to the class of drug, the quantity of drug consumed, the patient's age and sex, and such concurrent factors as diabetes mellitus, excessive alcohol intake, e.g. high caloric diet, which can lead to NAFLD/steatosis, or the use of other medications. Drugs administered in higher doses are more likely to cause liver injury, especially drugs that require extensive hepatic metabolism1. Different forms of drug-induced elevation of liver enzymes can be differentiated according to localisation of the injury: hepatocellular or cholestatic liver injury or a mixture of both.Besides methotrexate and isozid, other medications have been reported to induce hepatocellular liver injury: acarbose, allopurinol, amiodarone, baclofen, bupropion, fluoxetine, ketoconazole, lisinopril, losartan, non-steroidal anti-inflammatory drugs (NSAIDs), omeprazole, paracetamol, paroxetine, pyrazinamide, rifampicin, risperidone, sertraline, statins, tetracyclines, trazodone, and valproic acid. Silymarin containing oral preparations are widely used for their liver protecting characteristics. The milk thistle ingredient silibinin is registered for continuous intravenous administration in the case of acute liver intoxications such as consumption of amanita mushrooms. Although its mode of action is still not clear, the clinical therapeutic benefits in patients with liver diseases are documented. Pharmacokinetics of silymarin after oral administration are well understood. Due to its poor solubility in aqueous media, absorption from the intestinal tract is generally limited. Silymarin's systemic bioavailability of marketed products is therefore rather low, also because of predominant first pass biliary elimination. Exact PK/PD relations of the compound have not been assessed so far. Hence, in this clinical study silymarin will be administered in different dosages and compared to placebo in order to address the following question: Can liver protecting features of silymarin, measured by changes of liver enzyme concentration, be improved in patients with drug-induced elevated liver enzymes or drug-induced hepatocellular liver injury with higher systemic bioavailabilities due to administration of higher oral dosages or administration of higher administration frequency over a 35-day treatment period?


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 156
Est. completion date December 31, 2022
Est. primary completion date December 31, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: Evidence of hepatocellular drug-induced injury due to treatment* - ALT/AP ratio = 5 ((ALT level/ALT upper limit of normal (ULN))/(AP level/AP ULN)) OR Evidence of drug-induced elevation of liver-enzymes - ALT > 40 U/L and = 2 x ULN - ALT (> 40 U/L) = 2 weeks and = 3 months 3. Documentation (within the last 4 weeks before screening) of exclusion of liver tissue damage using either ultrasonography of the liver or Fibroscan with results = 7 kPa (fibrosis score of F0 to F1) 4. BMI = 18 and = 30 5. Liver enzyme elevation inducing medication stable for = 8 weeks before screening in the discretion of the treating physician 6. Written informed consent, after having been informed about potential benefit and potential risks of the clinical trial 7. Willing and capable to understand informed consent and follow the protocol Exclusion Criteria: 1. Use of silymarin within the last 6 months 2. Current intake and intake within the last 4 weeks of drugs that have been shown to induce cholestatic or mixed hepatocellular/cholestatic liver injury (inducing cholestatic liver injury: amoxicilline and clavulanic acid, anabolic steroids, chlorpromazine, clopidogrel, erythromycin, irbesartan, mirtazapine, estrogen, terbinafine; inducing mixed liver injury: amitriptyline, azathioprine, captopril, carbamazepine, clindamycin, co-trimoxazole, cyproheptadine, enalapril, flutamide, nitrofurantoin, phenobarbital, phenytoin, sulphonamide, trazodone, verapamil) 3. Patients with chronic liver disease, existing fibrosis or cirrhosis 4. Patients with acute viral hepatitis, autoimmune hepatitis or immune-mediated hepatitis (e.g., with immune checkpoint inhibitor treatment), acute Budd-Chiari syndrome, Wilson disease, and ischemic liver injury 5. Cholestatic or mixed hepatocellular/mixed liver injury 6. Patients with diabetes types 1 or 2 7. Any malignancy within the past 5 years 8. Patients with chronic intestinal diseases (e.g., ulcerative colitis) and intestinal barrier dysfunction in the discretion of the treating physician (e.g., patient can be included if disease is judged as stable by the treating physician with no likely interference with the study outcomes and the safety of the patient) 9. Evidence of significant uncontrolled concomitant diseases or serious and/or uncontrolled diseases that are likely to interfere with the evaluation of the patient's safety and of the study outcome 10. History of relevant central nervous system (CNS) and/or psychiatric disorders and/or currently treated CNS and/or psychiatric disorders 11. Known allergic reactions to the active ingredients used or to constituents of the pharmaceutical preparations, e.g. milk thistle, soy oil, peanut (according to Summary of Product Characteristics (SmPc)) 12. Contraindications to use the investigational medicinal product (IMP), e.g. hereditary galactose intolerance, genetic lactase deficiency or glucose-galactose malabsorption (according to SmPC) 13. Subjects with severe or moderate allergies or multiple drug allergies unless it is judged as not relevant for the clinical trial by the investigator 14. Laboratory values other than target parameters out of normal range unless the deviation from normal is judged as not relevant for the clinical trial by the investigator 15. Positive anti-HIV-test, antiHBs- or anti-HCV-test at Screening 16. History of or current drug or alcohol dependence 17. Subjects with a positive drug test at screening (incl. alcohol) 18. Regular intake of alcoholic food or beverages of = 40 g pure ethanol for male or = 20 g pure ethanol for female per day 19. Participation in a clinical trial during the last two months prior to individual enrolment of the subject or current participation 20. Use of drugs during the last two weeks prior Baseline that can affect absorption (e.g. laxatives, metoclopramide, loperamide, antacids, H2-receptor antagonists) 21. Subjects who are unable to understand the written and verbal instructions, in particular regarding the risks and inconveniences they will be exposed to during their participation in the clinical trial 22. Subjects who do not agree to apply adequate contraceptive methods as defined in Note for Guidance on Non-Clinical Safety Studies for the Conduct of Human Clinical Trials for Pharmaceuticals (CPMP/ICH/286/95, modification), November 2000

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Placebo
1 capsule per day of placebo
2x 140 mg per day
2 capsule per day of silimarit
3x 280 mg per day
3 capsule per day of silimarit
1x 1120 mg
8 capsule per day of silimarit

Locations

Country Name City State
Germany CIRI Frankfurt Hessia
Germany Universtity Hospital - clinic for dermatology, venerology and allergology Frankfurt Hessia

Sponsors (2)

Lead Sponsor Collaborator
Dr. Frank Behrens Bionorica SE

Country where clinical trial is conducted

Germany, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in blood ALT (Alanine-Aminotransferase) in IU/L Change in blood ALT in IU/Lin all treatment groups at day 35
Secondary Liver enzyme blood parameter AST (Aspartate-Aminotransferase) Change of Liver enzyme blood parameter AST in IU/Lin all treatment groups Baseline (prior treatment)
Secondary Liver enzyme blood parameter AST Change of Liver enzyme blood parameter AST in IU/Lin all treatment groups Day 7
Secondary Liver enzyme blood parameter AST Change of Liver enzyme blood parameter AST in IU/Lin all treatment groups Day 14
Secondary Liver enzyme blood parameters: AST Change of Liver enzyme blood parameter AST in IU/Lin all treatment groups Day 21
Secondary Liver enzyme blood parameter AST Change of Liver enzyme blood parameter AST in IU/Lin all treatment groups Day 28
Secondary Change Liver enzyme blood parameter AST Change of Liver enzyme blood parameter AST in IU/Lin all treatment groups Day 35
Secondary Change Liver enzyme blood parameter ALT Change of Liver enzyme blood parameter ALT in IU/Lin all treatment groups Baseline
Secondary Change Liver enzyme blood parameter ALT Change of Liver enzyme blood parameter ALT in IU/Lin all treatment groups Day 7
Secondary Change Liver enzyme blood parameter ALT Change of Liver enzyme blood parameter ALT in IU/Lin all treatment groups Day 14
Secondary Change Liver enzyme blood parameter ALT Change of Liver enzyme blood parameter ALT in IU/Lin all treatment groups Day 21
Secondary Change Liver enzyme blood parameter ALT Change of Liver enzyme blood parameter ALT in IU/Lin all treatment groups Day 28
Secondary Change Liver enzyme blood parameter ALT Change of Liver enzyme blood parameter ALT in IU/Lin all treatment groups Day 35
Secondary Change Liver enzyme blood parameter GGT (Gamma-Glutamyl-Transferase) Change of Liver enzyme blood parameter GGT in IU/Lin all treatment groups Baseline
Secondary Change Liver enzyme blood parameter GGT (Gamma-Glutamyl-Transferase) Change of Liver enzyme blood parameter GGT in IU/Lin all treatment groups Day 7
Secondary Change Liver enzyme blood parameter GGT (Gamma-Glutamyl-Transferase) Change of Liver enzyme blood parameter GGT in IU/Lin all treatment groups Day 14
Secondary Change Liver enzyme blood parameter GGT (Gamma-Glutamyl-Transferase) Change of Liver enzyme blood parameter GGT in IU/Lin all treatment groups Day 21
Secondary Change Liver enzyme blood parameter GGT (Gamma-Glutamyl-Transferase) Change of Liver enzyme blood parameter GGT in IU/Lin all treatment groups Day 28
Secondary Change Liver enzyme blood parameter GGT (Gamma-Glutamyl-Transferase) Change of Liver enzyme blood parameter GGT in IU/Lin all treatment groups Day 35
Secondary Change Liver enzyme blood parameter AP (Alkaline phosphatase ) Change of Liver enzyme blood parameter AP in IU/Lin all treatment groups Baseline
Secondary Change Liver enzyme blood parameter AP (Alkaline phosphatase ) Change of Liver enzyme blood parameter AP in IU/Lin all treatment groups Day 7
Secondary Change Liver enzyme blood parameter AP (Alkaline phosphatase ) Change of Liver enzyme blood parameter AP in IU/Lin all treatment groups Day 14
Secondary Change Liver enzyme blood parameter AP (Alkaline phosphatase ) Change of Liver enzyme blood parameter AP in IU/Lin all treatment groups Day 21
Secondary Change Liver enzyme blood parameter AP (Alkaline phosphatase ) Change of Liver enzyme blood parameter AP in IU/L in all treatment groups Day 28
Secondary Change Liver enzyme blood parameter AP (Alkaline phosphatase ) Change of Liver enzyme blood parameter AP in IU/L in all treatment groups Day 35
Secondary Change Liver enzyme blood parameter bilirubin Change of Liver enzyme blood parameter bilirubin in all treatment groups Baseline
Secondary Change Liver enzyme blood parameter bilirubin Change of Liver enzyme blood parameter bilirubin in all treatment groups Day 7
Secondary Change Liver enzyme blood parameter bilirubin Change of Liver enzyme blood parameter bilirubin in all treatment groups Day 14
Secondary Change Liver enzyme blood parameter bilirubin Change of Liver enzyme blood parameter bilirubin in all treatment groups Day 21
Secondary Change Liver enzyme blood parameter bilirubin Change of Liver enzyme blood parameter bilirubin in all treatment groups Day 28
Secondary Change Liver enzyme blood parameter bilirubin Change of Liver enzyme blood parameter bilirubin in all treatment groups Day 35
Secondary Change Liver enzyme blood parameter INR (International Normalized Ratio) Change of Liver enzyme blood parameter INR in all treatment groups baseline
Secondary Change Liver enzyme blood parameter INR (International Normalized Ratio) Change of Liver enzyme blood parameter INR in all treatment groups Day 7
Secondary Change Liver enzyme blood parameter INR (International Normalized Ratio) Change of Liver enzyme blood parameter INR in all treatment groups Day 14
Secondary Change Liver enzyme blood parameter INR (International Normalized Ratio) Change of Liver enzyme blood parameter INR in all treatment groups Day 21
Secondary Change Liver enzyme blood parameter INR (International Normalized Ratio) Change of Liver enzyme blood parameter INR in all treatment groups Day 28
Secondary Change Liver enzyme blood parameter INR (International Normalized Ratio) Change of Liver enzyme blood parameter INR in all treatment groups Day 35
Secondary Change Liver enzyme blood parameter Quick value Change of Liver enzyme blood parameter Quick value in all treatment groups baseline
Secondary Change Liver enzyme blood parameter Quick value Change of Liver enzyme blood parameter Quick value in all treatment groups Day 7
Secondary Change Liver enzyme blood parameter Quick value Change of Liver enzyme blood parameter Quick value in all treatment groups Day 14
Secondary Change Liver enzyme blood parameter Quick value Change of Liver enzyme blood parameter Quick value in all treatment groups Day 21
Secondary Change Liver enzyme blood parameter Quick value Change of Liver enzyme blood parameter Quick value in all treatment groups Day 28
Secondary Change Liver enzyme blood parameter Quick value Change of Liver enzyme blood parameter Quick value in all treatment groups Day 35
Secondary Change ALT/AP ratio Change of ALT/AP ratio in all treatment groups baseline
Secondary Change ALT/AP ratio Change of ALT/AP ratio in all treatment groups Day 7
Secondary Change ALT/AP ratio Change of ALT/AP ratio in all treatment groups Day 14
Secondary Change ALT/AP ratio Change of ALT/AP ratio in all treatment groups Day 21
Secondary Change ALT/AP ratio Change of ALT/AP ratio in all treatment groups Day 28
Secondary Change ALT/AP ratio Change of ALT/AP ratio in all treatment groups Day 35
Secondary Lipids analysis LDL (Low Density Lipoproteins) in all treatment groups Baseline
Secondary Lipids analysis LDL LDL (Low Density Lipoproteins) in all treatment groups Day 7
Secondary Lipids analysis LDL LDL (Low Density Lipoproteins) in all treatment groups Day 14
Secondary Lipids analysis LDL LDL (Low Density Lipoproteins) in all treatment groups Day 21
Secondary Lipids analysis LDL LDL (Low Density Lipoproteins) in all treatment groups Day 28
Secondary Lipids analysis LDL LDL (Low Density Lipoproteins) in all treatment groups Day 35
Secondary Lipids analysis HDL (High Density Lipoproteins) in all treatment groups baseline
Secondary Lipids analysis HDL (High Density Lipoproteins) in all treatment groups Day 7
Secondary Lipids analysis HDL (High Density Lipoproteins) in all treatment groups Day 14
Secondary Lipids analysis HDL (High Density Lipoproteins) in all treatment groups Day 21
Secondary Lipids analysis HDL (High Density Lipoproteins) in all treatment groups Day 28
Secondary Lipids analysis HDL (High Density Lipoproteins) in all treatment groups Day 35
Secondary Lipids analysis VLDL (very low Density Lipoproteins) in all treatment groups Day baseline
Secondary Lipids analysis VLDL VLDL (very low Density Lipoproteins) in all treatment groups Day 7
Secondary Lipids analysis VLDL VLDL (very low Density Lipoproteins) in all treatment groups Day 14
Secondary Lipids analysis VLDL VLDL (very low Density Lipoproteins) in all treatment groups Day 21
Secondary Lipids analysis VLDL VLDL (very low Density Lipoproteins) in all treatment groups Day 28
Secondary Lipids analysis VLDL VLDL (very low Density Lipoproteins) in all treatment groups Day 35
Secondary Lipids analysis triglycerides triglycerides in all treatment groups baseline
Secondary Lipids analysis triglycerides triglycerides in all treatment groups Day 7
Secondary Lipids analysis triglycerides triglycerides in all treatment groups Day 14
Secondary Lipids analysis triglycerides triglycerides in all treatment groups Day 21
Secondary Lipids analysis triglycerides triglycerides in all treatment groups Day 28
Secondary Lipids analysis triglycerides triglycerides in all treatment groups Day 35
Secondary Lipids analysis total cholesterol total cholesterol in all treatment groups baseline
Secondary Lipids analysis total cholesterol total cholesterol in all treatment groups Day 7
Secondary Lipids analysis total cholesterol total cholesterol in all treatment groups Day 14
Secondary Lipids analysis total cholesterol total cholesterol in all treatment groups Day 21
Secondary Lipids analysis total cholesterol total cholesterol in all treatment groups Day 28
Secondary Lipids analysis total cholesterol total cholesterol in all treatment groups Day 35
Secondary bloodparameter assessment fasting glucose value in all treatment groups baseline
Secondary bloodparameter assessment fasting glucose value in all treatment groups Day 7
Secondary blood parameter assessment fasting glucose value in all treatment groups Day 14
Secondary blood parameter assessment fasting glucose value in all treatment groups Day 21
Secondary blood parameter assessment fasting glucose value in all treatment groups Day 28
Secondary blood parameter assessment fasting glucose value in all treatment groups Day 35
Secondary Proportion of patients with normalization in liver enzyme blood parameters normalisation of liver enzyme blood parameters such as AST (< 40 IU/L), ALT (< 40 IU/L), GGT, AP, bilirubin, INR, Quick Day 35
Secondary Plasma silymarin dose concentration concentration of silymarin Base line
Secondary Plasma silymarin dose concentration concentration of silymarin day 7
Secondary Plasma silymarin dose concentration concentration of silymarin day 14
Secondary Plasma silymarin dose concentration concentration of silymarin day 21
Secondary Plasma silymarin dose concentration concentration of silymarin day 28
Secondary Plasma silymarin dose concentration concentration of silymarin day 35
Secondary Fibroscan value measurement of Fibroscan baseline
Secondary Fibroscan value measurement of Fibroscan day 14
Secondary Fibroscan value measurement of Fibroscan day 35
Secondary Fibrosis score score F0 to F4 baseline
Secondary Fibrosis score score F0 to F4 Day 14
Secondary Fibrosis score score F0 to F4 Day 35
Secondary CAP score score measured in dB/m baseline
Secondary CAP score score measured in dB/m day 14
Secondary CAP score score measured in dB/m day 35
Secondary Body Mass Index (BMI) index measured in weight and height baseline
Secondary Silymarin concentration in blood plasma in pharmakokinetic substudy - AUC assessement of area under the curve (AUC), baseline
Secondary Silymarin concentration in blood plasma in pharmakokinetic substudy - tmax assessement of time to maximal concentration (tmax) baseline
Secondary Silymarin concentration in blood plasma in pharmakokinetic substudy - Cmax assessement of maximal concentration (Cmax) baseline
Secondary Treatment adherence measured by patient diary Baseline
Secondary Treatment adherence measured by patient diary Day 7
Secondary Treatment adherence measured by patient diary Day 14
Secondary Treatment adherence measured by patient diary Day 21
Secondary Treatment adherence measured by patient diary Day 28
Secondary Treatment adherence measured by patient diary Day 35
Secondary quality of life measurements measured by short form survey (SF36) questionnaire baseline
Secondary quality of life measurements measured by short form survey (SF36) questionnaire Day 7
Secondary quality of life measurements measured by short form survey (SF36) questionnaire Day 14
Secondary quality of life measurements measured by short form survey (SF36) questionnaire Day 21
Secondary quality of life measurements measured by short form survey (SF36) questionnaire Day 28
Secondary quality of life measurements measured by short form survey (SF36) questionnaire Day 35
See also
  Status Clinical Trial Phase
Recruiting NCT05517668 - Evaluation of the Efficacy of Fomepizole in the Treatment of Acetaminophen Overdose Phase 2
Recruiting NCT05060289 - A Prognostic Model for Drug-induced Liver Injury in China
Completed NCT03092817 - Adjunctive Corticosteroids for Tuberculous Meningitis in HIV-infected Adults (The ACT HIV Trial) Phase 3
Completed NCT03211208 - Assessing Antibiotic Induced Liver Injury for Stratification of Tuberculosis Patients
Not yet recruiting NCT02061826 - Establishment of Drug-induced Liver Injury Databases and Application of Circulating microRNA(miRNA) N/A
Completed NCT02182167 - A Trial Of Intravenous N-Acetylcysteine In The Management Of Antituberculous Drug-Induced Hepatitis Phase 2/Phase 3
Completed NCT03665402 - A Pharamcogenomic Study for Isoniazid According to NAT2 Polymorphism Status N/A
Not yet recruiting NCT03060252 - Surveillance for Early Liver Injuries Caused by Zhuanggu Guanjie Pill N/A
Not yet recruiting NCT03091244 - Surveillance for Early Liver Injuries Caused by Xianlin Gubao Capsule. N/A
Not yet recruiting NCT03091556 - Surveillance for Early Liver Injuries Caused by Xianlin Gubao Pill. N/A
Not yet recruiting NCT03091608 - Surveillance for Early Liver Injuries Caused by Xianlin Gubao Granule N/A
Not yet recruiting NCT03091218 - Surveillance for Early Liver Injuries Caused by Runzao Zhiyang Capsule. N/A
Completed NCT02407964 - A Retrospective Study on Drug Induced Liver Injury in China N/A
Completed NCT01705041 - Preliminary Evaluation of a Point-Of-Care Liver Function Test N/A
Recruiting NCT02086708 - Ultrasound Method to Measure Fibrosis of the Liver in Children N/A
Recruiting NCT05465642 - Alterations of Gut Microbiota and Serum Biochemical Markers in DILI Patients
Completed NCT01434173 - Risk of Acute Liver Injury in Users of Antimicrobials N/A
Completed NCT05532345 - Discrimination of DILI and AIH by Artificial Intelligence
Completed NCT03602703 - Immune Responses in Hepatocellular Carcinoma Patients After Treatment With Direct Acting Antiviral Drugs
Active, not recruiting NCT03100786 - Leukotriene A4 Hydrolase Stratified Trial of Adjunctive Corticosteroids for HIV-uninfected Adults With Tuberculous Meningitis Phase 3